In the meantime, the treatment of fisetin suggestively decreases the MNU-induced bladder tumor incidence via decreasing the activation of NF-κB and modulating the NF-κB expression target genes that control cell apoptosis and cell proliferation. This evidence concerns the gene NFKB1 and urinary bladder neoplasm.